Highest-materiality recent filing
Pluri Inc. EIB loan discussions continue past July 3 deadline; no resolution yet
EIB loan of up to €50M; first tranche €20M disbursed June 2021 at 4% interest, originally due June 1, 2026.
Pluri receives Nasdaq delisting notice for failing MVLS minimum of $35M
Received Nasdaq notice on July 7, 2026 for non-compliance with MVLS minimum of $35M.
Received $1,250,000 advance from Chutzpah Holdings LP (beneficially owned by chairman Alexandre Weinstein) for working capital, to be applied toward future offering by Aug 14, 2026.
Pluri gets EIB nod for loan talks; no enforcement until July 3 on €20M maturing today
€20M EIB loan at 4% interest matured on June 1, 2026; only first tranche of €50M facility was drawn.
Pluri receives Nasdaq delisting notice for failure to meet $35M market value of listed securities
Nasdaq notified Pluri on Jan. 20, 2026 that its market value of listed securities fell below the required $35M minimum.
Pluri raises $2.5M via private placement to director; appoints Chairman
Enters securities purchase agreement for 625,000 common shares and warrants at $4.00/unit; gross proceeds ~$2.5M.
Pluri loses director Birger, triggering Nasdaq audit committee non-compliance with cure period
Doron Birger not re-elected at June 30 annual meeting; received 1,270,717 for, 2,720,350 against.
Pluri regains Nasdaq compliance on market value requirement; delisting risk resolved
On May 7, 2025, Nasdaq notified Pluri that it has regained compliance with Listing Rule 5550(b)(2) – market value of listed securities >= $35M for 10 consecutive business days (Apr 22 – May 6).
Pluri exchanges 976,139 shares for pre-funded warrants exercisable after shareholder approval
Pluri amended the Jan 2025 Securities Purchase Agreement with Chutzpah Holdings (Alejandro Weinstein, director) to exchange 976,139 common shares for pre-funded warrants.
Pluri Biotech Ltd. received termination notice from NIAID for a $4.2M contract awarded July 2023 to develop PLX-R18 for Hematopoietic Acute Radiation Syndrome.
Pluri to acquire 71.1% of Kokomodo for $4.5M in stock (12.14% dilution); related party deal
Purchase price $4.5M payable in 976,139 Pluri common shares (12.14% of fully diluted shares as of Jan 23, 2025).
Pluri raises $3.5M via private placement at $4.61/share with warrants to existing shareholder
Gross proceeds of ~$3.5M from sale of 759,219 shares at $4.61 each.
Pluri raises $6.5M private placement, signs term sheet to acquire 71% of Kokomodo for $4.5M in stock
Private placement: 1,383,948 common shares at $4.61 each, plus pre-funded and common warrants; gross proceeds ~$6.5M.
Previously reported non-compliance with Nasdaq Listing Rule 5550(b)(1) requiring $2.5M stockholders' equity.
Pluri receives Nasdaq delisting notice for failing $2.5M equity requirement
Nasdaq notified Pluri on Nov 25, 2024 of noncompliance with Listing Rule 5550(b)(1) for stockholders' equity below $2.5M.
Pluri Inc. regains Nasdaq compliance on stockholders' equity requirement
Received Nasdaq letter on Sept 26, 2024 confirming regained compliance with $2.5M stockholders' equity requirement.
Pluri receives Nasdaq extension to Nov 24, 2024 to regain $2.5M equity requirement
Deficiency letter issued May 28, 2024 for failing Nasdaq's $2.5M stockholders' equity minimum.
Pluri signs €1M proof-of-concept agreement with international agriculture corporation
Agreement value of €1 million, payable in three installments; first upon signing.
Pluri's subsidiary Ever After Foods raises $10M; license expanded to seafood
Ever After Foods raised $10M in private placement; Pluri invested $1,250,000.
Pluri receives Nasdaq deficiency notice for failing to meet $2.5M min equity requirement
Received deficiency letter from Nasdaq on May 28, 2024 for non-compliance with minimum stockholders' equity of $2.5M.
Pluri Inc. regains Nasdaq minimum bid price compliance
Nasdaq staff determined closing bid price ≥ $1.00 for 10 consecutive business days April 1-12, 2024.
Pluri receives Nasdaq extension to April 2024 for bid price compliance; transfers to Capital Market
Received 180-day extension until April 15, 2024 to regain minimum $1.00 bid price.
Pluri signs $4.2M NIAID contract to develop PLX-R18 cell therapy for H-ARS
Three-year, $4.2M contract with NIAID to advance PLX-R18 for Hematopoietic Acute Radiation Syndrome (H-ARS).
Pluri receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Pluri on April 19, 2023 that its common stock bid price closed below $1.00 for 30 consecutive trading days.
Pluri raises ~$8.4M in private placement of shares and warrants; CEO salary reduction for equity
Private placement of 8,020,900 common shares at $1.03–$1.09 per share with matching warrants exercisable for 3 years.
Pluri receives Nasdaq bid price deficiency notice; has until April 2023 to comply
Notice on Oct 12, 2022: common stock bid price closed below $1.00 for 30 consecutive days.
Pluri signs biologics API collaboration, cuts cash burn 30%, holds $56M cash
New collaboration with European API manufacturer for liver/gastro drugs; revenue expected in coming months.
Primary endpoint SPPB at week 26 not met; PLX-PAD showed no significant improvement vs placebo.
On June 19, 2026, the Board elected Mr. Doron Shorrer to serve as a member of the Board, effective immediately, to fill an existing vacancy on the Board created by the end of the service of Mr. Ajchenbaum
Mr. Eitan Ajchenbaum was not re-elected to the Board and therefore ceased to serve as a director and as a member of the respective committees on which he served, effective from the close of day of the 2026 Annual Meeting.
On July 2, 2024, the Board of Directors of the Company appointed Liat Zalts, age 40, to serve as the Company’s Chief Financial Officer and Treasurer effective as of September 30, 2024.
On June 30, 2024, Ms. Chen Franco-Yehuda notified Pluri Inc. (the “Company”) of her resignation from her position as Chief Financial Officer, Treasurer and Secretary of the Company, which will become effective as of September 30, 2024.
On July 11, 2023, the board of directors (the “Board”) of Pluri Inc. (the “Company”) appointed Mr. Lorne Abony to serve as a member of the Board, effective immediately, to hold office until the next meeting of shareholders of the Company at which directors are being elected or as set forth in the Company’s bylaws.
On July 15, 2021, the board of directors, or the Board, of Pluristem Therapeutics Inc., or the Company, appointed Prof. Varda Shalev and Mr. Doron Birger to serve as members of the Board, effective immediately,
On July 15, 2021, the board of directors, or the Board, of Pluristem Therapeutics Inc., or the Company, appointed Prof. Varda Shalev and Mr. Doron Birger to serve as members of the Board, effective immediately,
Max materiality 0.85 · Median 0.60 · Most common event other_material